This finding indicates a possible link between inflammatory modulation and CML progression, supporting the hypothesis that patients experiencing a favorable disease progression have an increased PTGS1 expression. This evidence concerns the gene PTGS1 and chronic myelogenous leukemia, BCR-ABL1 positive.